Efficacy and Safety of Ammoxetine in Major Depressive Disorder: A Randomized Clinical Trial.

ABSTRACT:

Importance

Major depressive disorder (MDD) is among the most prevalent mental health disorders, causing substantial disability and economic burden. Although several first-line treatments exist with mild adverse effects, up to 50% to 60% of patients do not tolerate or respond to them. Ammoxetine, a novel selective serotonin and norepinephrine reuptake inhibitor, has been found to reduce adverse effects and hepatotoxicity and more potent inhibition of serotonin and norepinephrine transporters, making it more tolerable and effective.

Objective

To evaluate the efficacy and safety of ammoxetine in treating adults with MDD.

Design, setting, and participants

This phase 2 randomized clinical trial was a multicenter, double-masked, placebo-controlled, parallel-group, fixed-dos

SUBMITTER: He S 

PROVIDER: S-EPMC12455369 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature